Secretory clusterin (sCLU) overexpression is associated with resistance to preoperative neoadjuvant chemotherapy in primary breast cancer

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 10, 2013, Pages 1337-1344

  Niu, Z H ^a   Wang, Y ^a   Chun, B ^a   Li, C X ^a   Wu, L ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Breast cancer; Chemotherapy; Clusterin

Indexed keywords

CLUSTERIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GLYCOSYLATED PROTEIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREOPERATIVE PERIOD; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLUSTERIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878552307     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. KOMENAKA IK, HIBBARD ML, HSU CH, LOW BG, SALGANICK JA, BOUTON ME, JHA C. Preoperative chemotherapy for operable breast cancer improves surgical outcomes in the community hospital setting. Oncologist 2011; 16: 752-759.
2. SPECHT J, GRALOW JR. Neoadjuvant chemotherapy for locally advanced breast cancer. Semin Radiat Oncol 2009; 19: 222-228.
3. KAUFMANN M, VON MINCKWITZ G, RODY A. Preoperative (neoadjuvant) systemic treatment of breast cancer. Breast 2005; 14: 576-581.
4. VON MINCKWITZ G, RAAB G, SCHÜTTE M, HILFRICH J, BLOHMER JU, GERBER B, COSTA SD, MERKLE E, EIDTMANN H, LAMPE D, JACKISCH C, DU BOIS A, TULUSAN AH, GADEMANN G, SINN HP, CAPUTO A, GRAF E, KAUFMANN M. Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc)-Experience of the GEPARDO-GABG study group. Zentralbl Gynakol 2001; 123: 497-504.
5. FISCHER B, BROWN A, MAMOUNAS E, WIEAND S, ROBIDOUX A, MARGOLESE RG, CRUZ AB JR, FISHER ER, WICKERHAM DL, WOLMARK N, DECILLIS A, HOEHN JL, LEES AW, DIMITROV NV. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 2483-2493.
6. DJEU JY, WEI S. Clusterin and chemoresistance. Adv Cancer Res 2009; 105: 77-92.
7. SOWERY RD, HADASCHIK BA, SO AI, ZOUBEIDI A, FAZLI L, HURTADO-COLL A, GLEAVE ME. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int 2008; 102: 389-397.
8. ZELLWEGER T, MIYAKE H, JULY LV, AKBARI M, KIYAMA S, GLEAVE ME. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 2001; 3: 360-367.
9. SO A, SINNEMANN S, HUNTSMAN D, FAZLI L, GLEAVE M. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol Cancer Ther 2005; 4: 1837-1849
10. JULY LV, BERALDI E, SO A, FAZLI L, EVANS K, ENGLISH JC, GLEAVE ME. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther 2004; 3: 223-232
11. KAKLAMANI VG, GRADISHAR WJ. Adjuvant therapy of breast cancer. Cancer Invest 2005; 23: 548-560.
12. REDONDO M, VILLAR E, TORRES-MUÑOZ J, TELLEZ T, MORELL M, PETITO CK. Overexpression of clusterin in human breast carcinoma. Am J Pathol 2000; 157: 393-399.
13. TROUGAKSO IP, SO A, JANSEN B, GLEAVE ME, GONOS ES. Silencing expression of the clusterin/apolipoprotein J gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 2004; 64: 1834-1842.
14. PUCCI S, BONANNO E, PICHIORRI F, ANGELONI C, SPAGNOLI LG. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 2004; 23: 2298-2304.
15. MIYAKE H, HARA I, GLEAVE ME, ETO H. Protection of androgendependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. Prostate 2006; 61: 318-323.
16. ZELLWEGER T, KIYAMA S, CHI K, MIYAKE H, ADOMAT H, SKOV K, GLEAVE ME. Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU Int 2003; 92: 463-469
17. MIYAKE H, HARA I, KAMIDONO S, GLEAVE ME, ETO H. Resistance to cytotoxic chemotherapy induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. Oncol Rep 2003; 10: 469-473.
18. SCALTRITI M, BRAUSI M, AMOROSI A, CAPORALI A, D'ARCA D, ASTANCOLLE S, CORTI A, BETTUZZI S. Clusterin (SGP-2, APOJ) expression is downregulated in low- and high-grade human prostate cancer. Int J Cancer 2008; 108: 23-30.
19. VAN WEELDEN K, FLANAGAN L, BINDERUP L, TENNISWOOD M, Welsh JE. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analogue, EB1089. Endocrinology 1998; 139: 2102-2110.
20. REDONDO M, VILLAR E, TORRES-MUNOZ J, TELLEZ T, MORELL M, PETITO CK. Overexpression of clusterin in human breast carcinoma. Am J Pathol 2006, 157: 393-399.
21. MIYAKE H, HARA I, KAMIDONO S AND GLEAVE ME. Synergistic chemosensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 2001; 7: 4245-4252.
22. YOM CK, WOO HY, MIN SY, KANG SY, KIM HS. Clusterin overexpression and relapse-free survival in breast cancer. Anticancer Res 2009; 29: 3909-3912.